Shots:
- Myra Vision received the US FDA conditional IDE approval to initiate its ADAPT study evaluating Calibreye Titratable Glaucoma Therapy (TGT) surgical system for glaucoma
- The IDE trial will evaluate the safety and efficacy of Calibreye TGT surgical system in ~70 refractory glaucoma pts with 12mos. primary effectiveness endpoint
- Calibreye System allows ophthalmologists to control aqueous outflow for personalized therapy with reduced complications, using an implanted shunt that allows slit lamp-based outflow adjustments as patient needs change
Ref: Myra Vision | Image: Myra Vision | Press Release
Related News:- TransMedics Receives FDA Conditional IDE Approval to Initiate OCS ENHANCE Heart Study
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
